AKT1 and cancer: For example, the gap junction protein GJB3 is being considered as a therapeutic target for a wide range of cancer types, including lung adenocarcinoma where the knockdown of the protein inhibits the PI3K/AKT pathway and leads to a decrease in proliferation, migration, and viability of cancer cells [96].